Why is Genmab stock sliding today?
Genmab (GMAB) shares fell 4.9% after Q3 revenue of $1.19B missed estimates, though EPS beat. Epkinly sales grew 47% but lagged Jyske Bank's forecast. Full-year guidance remained unchanged, disappointing some analysts. Higher costs reduced net profit. The company maintained its revenue and earnings outlook but did not raise it, despite recent clinical trial successes.
How this was made
The 30-second read
Why it matters
Earnings miss and flat guidance triggered a sell‑off, but the company still expects strong sales from Epkinly and Rina‑S later in the year.
Market read
The fresh earnings data caused a near‑5% intraday decline, offering a short‑term trading opportunity.
What to watch
Higher operating expenses reflect investment in pipeline; long‑term growth potential remains strong.
Background
Genmab is a Danish biotech focused on antibody therapeutics, trading ADR GMAB on Nasdaq.
Ticker impact
Genmab reported Q3 revenue of $1.19B, EPS $0.55 beat estimates but sales missed and guidance unchanged, causing a 4.9% drop.
likely further pressure as investors price in disappointment over flat guidance.
Earnings miss and no guidance lift are fresh primary facts that moved the stock 4.9% down on the day.
Market effects
Biotech sector may see modest pullback as earnings miss highlights execution risk.
Danish market shows limited support; broader European indices remain largely unchanged.
Limited to biotech investors; no major macro spillover.
Counterpoint
The miss may be temporary; pipeline progress and upcoming Phase 3 data could support a rebound.
Key entities
- companyGenmab
Danish biotech company reporting Q3 results.
- productEpkinly
Genmab's cancer drug with 47% sales growth.
